These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1664143)

  • 1. The modulation of alkylating agents.
    Frei E
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):22-4. PubMed ID: 1664143
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of antitumor alkylating agents (AA).
    Teicher BA; Frei E
    Cancer Treat Res; 1991; 57():261-95. PubMed ID: 1686721
    [No Abstract]   [Full Text] [Related]  

  • 3. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy--a review.
    Waxman DJ
    Cancer Res; 1990 Oct; 50(20):6449-54. PubMed ID: 2208103
    [No Abstract]   [Full Text] [Related]  

  • 4. [Resistance to cytostatic drugs].
    Elonen E
    Duodecim; 1998; 114(13):1319-28. PubMed ID: 11552258
    [No Abstract]   [Full Text] [Related]  

  • 5. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
    Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of glutathione in cellular resistance to alkylating agents.
    Colvin OM; Friedman HS; Gamcsik MP; Fenselau C; Hilton J
    Adv Enzyme Regul; 1993; 33():19-26. PubMed ID: 8356908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to alkylating agents.
    Colvin OM
    Cancer Treat Res; 1994; 73():249-62. PubMed ID: 7710907
    [No Abstract]   [Full Text] [Related]  

  • 8. Alkylating agents, mechanisms of resistance: a review.
    Fox BW
    Prog Clin Biol Res; 1983; 132C():247-55. PubMed ID: 6314356
    [No Abstract]   [Full Text] [Related]  

  • 9. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.
    Hasinoff BB; Wu X; Begleiter A; Guziec LJ; Guziec F; Giorgianni A; Yang S; Jiang Y; Yalowich JC
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):221-33. PubMed ID: 16010589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical experience with cisplatin resistance.
    Marshall JL; Andrews PA
    Hematol Oncol Clin North Am; 1995 Apr; 9(2):415-29. PubMed ID: 7642471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
    Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forced evolution of glutathione S-transferase to create a more efficient drug detoxication enzyme.
    Mulder GJ
    Hum Exp Toxicol; 1996 Feb; 15(2):181-2. PubMed ID: 8645507
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased DNA-repair capacity and the modulation of 2 proteins in and metallothionein overexpressing Chinese hamster cell line.
    Robson T; Grindley H; Hall A; Vormoor J; Lohrer H
    Mutat Res; 1994 Mar; 314(2):143-57. PubMed ID: 7510364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
    Pawlik CA; Israel M; Sweatman TW; Lothstein L
    Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of melphalan with glutathione and the role of glutathione S-transferase.
    Awasthi S; Bajpai KK; Piper JT; Singhal SS; Ballatore A; Seifert WE; Awasthi YC; Ansari GA
    Drug Metab Dispos; 1996 Mar; 24(3):371-4. PubMed ID: 8820431
    [No Abstract]   [Full Text] [Related]  

  • 17. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell survival recovery kinetics in the KHT sarcoma following treatment with five alkylating agents and misonidazole.
    Siemann DW; Mulcahy RT
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):619-22. PubMed ID: 7107384
    [No Abstract]   [Full Text] [Related]  

  • 19. Alkylating agents.
    Connors TA
    Cancer Chemother Biol Response Modif; 1992; 13():31-44. PubMed ID: 1389913
    [No Abstract]   [Full Text] [Related]  

  • 20. [Resistance associated with the glutathione system].
    Gouyette A
    Bull Cancer; 1994 Dec; 81 Suppl 2():69s-73s. PubMed ID: 7727862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.